SCHEMBL30149847

SCHEMBL30149847

COc1ccc(C(=C2CCN(C(=O)OC(C)(C)C)CC2)c2cccnc2)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.46
▸ GPR119 Q8TDV5 3/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ PDE4A P27815 2/20 0.45
▸ PDE4B Q07343 2/20 0.45
▸ PDE4C Q08493 2/20 0.45
▸ PDE4D Q08499 2/20 0.45
▸ USP2 O75604 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ PDGFRB P09619 1/20 0.44
▸ CFTR P13569 1/20 0.43
▸ CYP1A1 P04798 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23211806 1.00 POLB (0.46) POLBGPR119ALDH1A1KMT2AKDM4E
SCHEMBL30567965 1.00 POLB (0.46) POLBGPR119ALDH1A1KMT2AKDM4E
SCHEMBL29734416 0.88 LMNA (0.50) POLBGPR119ALDH1A1KMT2AMEN1
SCHEMBL22491440 0.88 LMNA (0.50) POLBGPR119ALDH1A1KMT2AMEN1
SCHEMBL23211976 0.87 POLB (0.50) POLBALDH1A1KMT2AKDM4EMEN1
SCHEMBL22491587 0.82 PTAFR (0.51) POLBGPR119ALDH1A1KMT2AKDM4E
SCHEMBL29734522 0.82 PTAFR (0.51) POLBGPR119ALDH1A1KMT2AKDM4E
SCHEMBL23212048 0.82 GPR119 (0.49) GPR119MAPK1CCNA2CDK2
SCHEMBL30568010 0.82 GPR119 (0.49) GPR119MAPK1CCNA2CDK2
SCHEMBL30149843 0.82 GPR119 (0.49) GPR119MAPK1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 — — US disclosed
EP-3768684-B1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN LA ROCHE (CH) 2023-02-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC POLB 1788/4885GPR119 432/4885ALDH1A1 1432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback